On the chessboard of social security policy, the issue of drugs has always been one of the most concerned issues for the Chinese public. Especially for patients with rare diseases and tumors, the high price of drugs has long been like an insurmountable mountain, overwhelming them.
However, with the continuous optimization of social security policies, this problem has been significantly improved. In 2023, we are pleased to see that medical insurance"Medicine basket"Another round of comprehensive upgrades has been ushered in.
The comprehensive update of the medical insurance drug list: the total number of drugs reached 3,088
The National Health Insurance Administration announced the results of the adjustment of the National Medical Insurance Drug List in 2023, and a total of 126 new drugs have been added to the medical insurance list. After the adjustment of the NRDL for the sixth consecutive year this year, 126 new drugs have been successfully included. This brings the total number of medical insurance catalogues to 3,088, including 1,698 Western medicines and 1,390 proprietary Chinese medicines。Looking ahead, this is undoubtedly good news for China's 1.3 billion insured people.
The new drugs cover many fields from anti-tumor to rare diseasesAs a result, it provides a richer and more professional medical choice for the majority of patients. In the past, the high cost of drugs made many patients feel powerless in the face of the disease, and even the heavy pressure made them bankrupt. Now, with the addition of these new drugs, the medical burden of the people will be greatly reduced, and it is indeed a "relief in the snow" for patients.
Of particular concern is,Among the new drugs, there are 15 first-class drugs for rare diseasesIncluding egolastat tartrate for adult patients with Gaucher disease type I, stuximab for Kastel disease, etc. The inclusion of these drugs fills the gap in the protection of drugs for 10 rare diseases, which in the past could not keep up with the drug development and production due to the small number of patients and the lack of motivation for drug development and market promotion, and many patients were therefore in a dilemma of no drugs available.
However, when these drugs are included in the medical insurance, it is expected to benefit nearly 10,000 patients, and nearly 10,000 families will rekindle their hope in life. This is a great safeguard of the dignity of life and a further realization of social justice.
Another example,In the field of oncology, the adjustment of the medical insurance drug list has also brought gratifying changes. For example, the newly introduced aclotinib is a new drug that can revolutionize mantle cell lymphosis. The use of drugs such as reboxiclib succinate has greatly reduced the cost of breast cancer**, allowing more patients to accept and adhere to the long-term**. These bring not only the improvement of the first effect, but more importantly, the hope of life for those patients who have given up the right to live.
In addition, the potential impact of innovative drugs in the 2023 medical insurance negotiations cannot be underestimated. It is known that 25 innovative drugs participated in the negotiations, with a success rate of 92%. The number of innovative drugs has been further depressed, which is of great significance for improving patients' ability to pay. It is estimated that in the next two years, the above 126 new drugs will help reduce the burden on patients by more than 40 billion yuan.
Every adjustment of the medical insurance policy represents that we are one step closer to the goal. The key to solving the problem of drug prices lies in innovation in policy design and implementation. We should give more recognition and support to innovative drugs at home and abroad, and encourage them to provide them to the people with more affordable products. Furthermore, we must promote the reform of the health care system to meet the needs of the people.
As an important pillar of China's medical system, the medical insurance system has much more than that. In the future, we look forward to a more complete medical insurance system that can ensure that all insured people receive better and more comprehensive drug coverage. The rich and diversified list of medical insurance drugs proves that China's social security policy is gradually developing in a more scientific and fair direction.
This adjustment of medical insurance policies in 2023 is undoubtedly a huge boon for patients. More importantly, it shows China's determination and perseverance in specifying a roadmap for health protection. And all this is inseparable from the joint efforts of every medical worker, social security expert, and even the whole society. Let's look forward to a better tomorrow and a healthy China.